DURECT Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DRRX research report →
About the company
DURECT Corporation is a biopharmaceutical enterprise dedicated to the research and development of innovative medicines, leveraging its epigenetic regulator and pharmaceutical platforms. The company provides the ALZET product range, which includes osmotic pumps and associated accessories vital for research studies conducted on mice, rats, and other laboratory animals. In its development pipeline, DURECT is advancing larsucosterol (DUR-928), an endogenous, orally administered small molecule.
- CEO
- James E. Brown D.V.M.
- IPO
- 2000
- Employees
- 21
- HQ
- Cupertino, CA, US
Price Chart
- Market Cap
- $59.31M
- P/E
- 51.62
- P/S
- 48.58
- P/B
- 15.06
- EV/EBITDA
- -4.99
- Div Yield
- 0.00%
- Gross Margin
- 91.97%
- Op Margin
- -1045.54%
- Net Margin
- 66.09%
- ROE
- 13.14%
- ROIC
- -188.15%
- Revenue
- $2.03M · -76.24%
- Net Income
- $-8,324,000 · 69.87%
- EPS
- $-0.27 · 77.87%
- Op Income
- $-18,912,000
- FCF YoY
- 44.62%
- 52W High
- $2.64
- 52W Low
- $0.48
- 50D MA
- $1.41
- 200D MA
- $0.91
- Beta
- 0.93
- Avg Volume
- 1.19M
Get TickerSpark's AI analysis on DRRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 11, 25 | BROWN JAMES E | sell | 103,077 |
| Sep 11, 25 | Robertson Judith J. | sell | 5,500 |
| Sep 11, 25 | Robertson Judith J. | sell | 5,500 |
| Sep 11, 25 | Robertson Judith J. | sell | 5,500 |
| Sep 11, 25 | Robertson Judith J. | sell | 5,500 |
| Sep 11, 25 | Robertson Judith J. | other | 41,113 |
| Sep 11, 25 | Robertson Judith J. | sell | 7,000 |
| Sep 11, 25 | BROWN JAMES E | other | 8,000 |
| Sep 11, 25 | BROWN JAMES E | sell | 96,959 |
| Sep 11, 25 | BROWN JAMES E | sell | 36,720 |
Our DRRX coverage
Recent articles, reports, and earnings notes.
No research on DRRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DRRX report →Similar companies
Peers in the same neighborhood.